Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Uniquely Suited To Build Pharma 3.0 From The Ground Up As Healthcare Reform Rolls Out

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - As the pharmaceutical industry begins to embrace new business models that utilize the newest advances in information technology to achieve better health outcomes, China may be uniquely suited to implement such a system from the ground up, Ernst & Young said during a life sciences roundtable discussion with local reporters in Shanghai March 25

You may also be interested in...



Reimbursement Expansion To Fuel China Device Growth In 2011 (Part 2 of 2)

[Editor's note: This is part two of a two-part story. Part one appeared in PharmAsia News, Feb. 22, 2011.]

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC077547

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel